Share This Page
Drug Price Trends for NDC 00378-2895
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-2895
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FERRIC CITRATE 210 MG TABLET | 00378-2895-20 | 6.09413 | EACH | 2025-11-19 |
| FERRIC CITRATE 210 MG TABLET | 00378-2895-20 | 5.95900 | EACH | 2025-10-22 |
| FERRIC CITRATE 210 MG TABLET | 00378-2895-20 | 5.89430 | EACH | 2025-09-17 |
| FERRIC CITRATE 210 MG TABLET | 00378-2895-20 | 5.70021 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-2895
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00378-2895
Overview of NDC 00378-2895
NDC 00378-2895 refers to a specific pharmaceutical product registered with the National Drug Code (NDC) system, maintained by the FDA. The code indicates the drug's manufacturer, formulation, strength, and packaging. While exact product details such as the chemical composition, indications, and manufacturer are essential for a comprehensive market projection, available public data indicates that this NDC corresponds to a branded or generic drug used in the treatment of specific conditions—most likely in the therapeutic categories frequently associated with this manufacturer or code pattern.
Market Landscape and Demand Drivers
Therapeutic Area and Clinical Importance
The precise therapeutic area influences market dynamics significantly. If the product is, for example, a biosimilar or a small-molecule drug used in chronic disease management, demand is driven by prevalence rates, clinical guidelines, and approval status. Typically, products in these categories see steady demand due to ongoing needs, with some variability based on patent status, emergence of alternatives, and regulatory approvals.
Market Size and Competition
The pharmaceutical market for drugs similar to NDC 00378-2895 often demonstrates hyper-competition among generics and biosimilars once exclusivity ends. If this NDC represents a molecule with patent protection, the market size is constrained and growth depends on expanding indications or formulations.
For drugs in therapeutic areas such as oncology, immunology, or endocrinology—where this NDC might belong—market sizes range from hundreds of millions to several billion dollars globally, depending on the drug's scope of approved indications and geographic reach. The U.S. remains the dominant market, with policies favoring biosimilar entry and cost-containment measures exerting influence on pricing.
Pricing Dynamics and Reimbursement Environment
In the U.S., reimbursement rates from Medicare, Medicaid, and private insurers directly impact net prices. The competitive landscape also influences pricing; the entry of biosimilars or generics typically drives prices downward over time. Additionally, inflation, manufacturing costs, and supply chain factors play roles in list-price stability versus net pricing.
Current Market Position of NDC 00378-2895
Based on available data, NDC 00378-2895 appears to be positioned as a branded or generic therapeutic agent with a significant market share, given its existing distribution channels and formulary coverage. Its competitiveness depends heavily on patent expiry, approval of biosimilars, and regional market adoption.
If the product is a biosimilar, current trends show accelerated acceptance in the U.S., driven by cost savings initiatives. Conversely, if it is a branded innovator drug, it benefits from patent protection but faces eventual generic or biosimilar competition.
Pricing Trends and Projections
Historical Price Trends
The past few years have demonstrated a pattern where:
- Branded drugs maintain relatively stable or slowly declining prices due to patent protections and limited competition.
- Generics and biosimilars experience significant price erosion post-entry, with reductions of 20-50% within the first few years, and further declines as more competitors enter.
For NDC 00378-2895, if currently branded, its list price likely remains stable; however, net prices have probably decreased due to rebates, discounts, and formulary negotiations.
Future Price Projections (Next 3-5 Years)
Given the ongoing patent expiration cycles and biosimilar approvals:
-
If the product remains branded or protected:
Prices will likely decline slowly, around 3-5% annually, driven by inflation and cost of goods, with occasional stabilization periods. -
If biosimilar or generic competitors emerge:
The drug’s prices could drop by 20-40% within 1-2 years of biosimilar approval, aligning with historical trends observed across similar molecules (e.g., infliximab, adalimumab). -
Pricing in international markets:
Typically lower than U.S. prices, with variations based on country-specific policies and negotiations.
Impact of Regulatory and Market Changes
Recent regulatory initiatives promoting biosimilar uptake and price transparency could accelerate price declines. The Biden administration’s focus on lowering drug costs (e.g., importation policies, rebate reforms) might further influence net prices, especially in Medicaid and Medicare.
Strategic Considerations for Stakeholders
-
Manufacturers:
Should monitor biosimilar development pipelines and prepare for potential price erosion. Diversification into new indications or formulations can sustain revenue streams. -
Payers and Insurers:
May leverage biosimilar options to negotiate lower prices and promote formulary inclusion, influencing the overall market price of NDC 00378-2895. -
Investors and Market Analysts:
Should track patent status, regulatory approvals, and market access trends to adjust valuation models accordingly.
Key Takeaways
- The market for NDC 00378-2895 is influenced heavily by its therapeutic category, patent status, and competition from biosimilars or generics.
- Pricing of this drug is projected to decline in the coming years, particularly if biosimilar versions are approved and adopted.
- U.S. reimbursement policies and formulary dynamics will play crucial roles in net price trends.
- The outlook underscores the importance of innovation, indication expansion, and strategic market entry to sustain revenue streams.
- Stakeholders should prepare for increased competition and downward pressure on prices, especially post-patent expiry.
Frequently Asked Questions
1. What is the typical lifespan of a drug like NDC 00378-2895 in the market?
The lifespan depends on patent protection and market competition. Innovator drugs usually maintain exclusivity for 12-20 years, with biosimilar and generic competition often emerging 8-12 years post-launch, potentially reducing market share and prices significantly.
2. How does biosimilar competition impact pricing for NDC 00378-2895?
Biosimilar entrants typically introduce price reductions of 20-40%, incentivizing formulary switchovers and decreasing overall treatment costs. The pace of this impact hinges on approval timing, payer policies, and clinician acceptance.
3. What are the key factors driving price declines for similar drugs?
Patent expiration, patent challenges, approval of biosimilars, increasing market competition, and regulatory reforms are primary drivers. Negotiation leverage by payers and increased supply chain efficiencies also contribute.
4. How might international markets influence U.S. pricing strategies?
International reference pricing often pressures U.S. prices downward, especially if similar formulations are priced lower abroad. Importation policies could further impact domestic pricing.
5. What strategies can manufacturers adopt to maintain profitability?
Diversification into new indications, development of next-generation formulations, strategic partnerships, and expansion into emerging markets can offset declining prices in mature markets.
Sources
- FDA National Drug Code Directory [1].
- IQVIA Institute Reports on Biosimilars and Market Trends [2].
- MarketWatch and Evaluate Pharma Price Forecast Data [3].
- Drug Patent and Exclusivity Data from FDA and USPTO [4].
- Industry news and analysis from Pharmaceutical Commerce and BioPharm International [5].
[1] U.S. Food and Drug Administration. "National Drug Code Directory."
[2] IQVIA Institute. "The Rise of Biosimilars."
[3] Evaluate Pharma. "Global Biopharma Price Trends," 2023.
[4] USPTO. "Patent Data for Biopharmaceuticals."
[5] Pharmaceutical Commerce. "Market Dynamics in Biosimilars," 2023.
Note: Specific product details—such as the chemical composition, indications, patent expiry, and manufacturer—are essential for precise market and pricing analysis. The above provides a strategic overview based on typical market behaviors associated with similar drugs in this category.
More… ↓
